The Infectious Disease Research Institute, a Seattle-based global health research center, said it has licensed two key components of an experimental leishmaniasis vaccine to research partners at the Instituto Butantan in Sao Paolo, Brazil. Under the deal, IDRI will receive royalty payments on sales if its partners develop a marketable vaccine for leishmaniasis, which affects an estimated 500,000 people around the world each year, and kills about one-tenth of those infected.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
